A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

NCT07669415 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: LM-168
DRUG: Tislelizumab
DRUG: Docetaxel injection

Sponsor

LaNova Medicines Limited